Video_1_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.WMV by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Video_2_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.WMV by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Video_4_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.WMV by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Image_1_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.JPEG by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Biologic activity of LY5 in sarcoma cell lines. by Peter Y. Yu (4281448)

Glucose-lowering efficacy. by Sungmin Kim (628527)

Subjects:

eGFR values and mean eGFR change after the use of dulaglutide. by Sungmin Kim (628527)

Subjects:

Baseline characteristics. by Sungmin Kim (628527)

Subjects:

The incidence rate of progression from microalbuminuria to proteinuria with dulaglutide use. by Sungmin Kim (628527)

Subjects:

Clinical factors affecting renal response to dulaglutide. by Sungmin Kim (628527)

Subjects:

The IC50 value of Tan in normal esophageal HET-1A cells. by Dong Yang (141041)

Assessment of exoprotein concentration in a 50-mL culture of MH96. by Marion Schoof (11999106)

The T37A substitution increases both H5N6 M1 protein stability and H5N6 viral replication in mammals. by Chenxi Wang (284364)

Effect of 2%, 4%, and 6% HQ cream on behavioral activities. by Huali Wu (349567)

“…<p>In open field test, a significant decrease was observed in the crossing (A) and rearing numbers (B) during 5minutes. …”

Subject demographic data in five-year buckets. by David Romero-Bascones (14265633)

Effect of 2% HQ, 0.05% INN and 0.1% TAC on behavioral activities in C57BL/6 mice. by Huali Wu (349567)

“…<p>In open field test, a significant decrease was observed in the crossing (A) and rearing numbers (B) of INN and TAC group during 5minutes, whereas no change in the number of grooming episodes (C). …”

(a) Tuberculosis (TB) incidence rate of 90 countries in 1990 and (b) TB mortality rate of 28 countries in 1950, according to the BCG vaccination status in 2015. by Kazuo Inoue (302545)

Involvement of prelimbic 5-HT₇ receptors in the regulation of anxiety-like behaviors in hemiparkinsonian rats by Cheng Xue Du (5496437)

“…Neurochemical results showed that intra-PrL injection of AS19 increased dopamine, 5-HT and noradrenaline (NA) levels in the medial prefrontal cortex, ventral hippocampus and amygdala in two groups of rats, whereas SB269970 decreased 5-HT and NA levels in these brain regions.…”

A representative PCV case of 83 years old man with a 95-month treatment period and 27-month persistent fluid. by Chang-Chi Weng (8362725)

Flowchart of patients. by Seydou Goro (17847203)

Subjects: